Source:http://linkedlifedata.com/resource/pubmed/id/12453854
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2002-11-27
|
| pubmed:abstractText |
This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer.
|
| pubmed:language |
eng
|
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:author | |
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1868-73
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:articleTitle |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
|
| pubmed:affiliation |
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden. bengt.glimelius@onkologi.uu.se
|